Jevremovic describes the use of flow cytometric analysis of bone marrow for the presence of dysplasia in chronic myeloid neoplasms. The test includes the triage panel and there is no need to order it separately. Favorable abnormalities: Utilization Message As you view this presentation, consider the following important points regarding Myeloid Blast and Maturation Assessment by Flow Cytometry. The results were statistically significant for abnormalities of granulocytes twice as common in AMLMRC , especially when we looked at cases with abnormalities of all three types of cells: An interactive calculation tool for chi-square tests of goodness of fit and independence [Computer software].
Cite this page: Issue Section:. Article Navigation.
Flow cytometric analysis is considered a useful ancillary tool for assessing myelodysplasia in MDS. The granulocytic abnormalities were seen in 22 of 48 AML cases and in 4 of 22 control cases.
By searching our database, we identified cases diagnosed as PMF with bone marrow specimens analyzed by flow cytometry at the time of initial evaluation at our institution during the period of January 2004 to August 2008.
Cytoplasmic granularity was assessed by measuring the median and the 10th percentile of side scatter height.
The findings are interpreted as normal, atypical and aberrant. The specific abnormalities in control cases are shown in Tables 1 and 2 and are described below.
Granulocyte, monocyte, and blast abnormalities were more common in AML than in controls, and the differences were statistically significant Table 4.
Abnormal myeloblasts pink with partial expression of CD103. Page views in 2018: The monocyte abnormalities were present in 23 of 48 AML cases and in 2 of 22 control cases.
Standardization of flow cytometry in myelodysplastic syndromes: Email alerts New issue alert.
Abnormal granulocytes blue with decreased expression of CD11c. A number of studies documented the association of granulocyte and monocyte immunophenotype abnormalities with myelodysplastic syndromes MDS [ 2 — 6 ] and myeloproliferative neoplasms MPN [ 7 ]. The control cases included reactive changes, lymphoid or plasma cell neoplasms, and specimens with no significant bone marrow abnormalities referred for work-up of cytopenias or cytosis.
The AML cases were divided into 3 groups: